---
title: "BIA-ALCL: Symptoms, Diagnosis and Treatment of Breast Implant-Associated Lymphoma"
url: https://drturner.com.au/blogs/bia-alcl-symptoms-diagnosis-and-treatment-of-breast-implant-associated-lymphoma/
date: 2021-11-12
modified: 2026-07-30
author: "Dr Scott J Turner"
description: "Dr Scott J Turner | Specialist Plastic Surgeon (FRACS) Key Takeaways BIA-ALCL is a rare cancer of immune cells that can develop in the fluid or scar capsule around certain..."
categories:
  - "Breast Implants"
tags:
  - "BIA-ALCL"
  - "BIA-ALCL Melbourne"
  - "Breast Implant-Associated Cancer"
  - "Breast Implant-Associated Cancer Melbourne"
  - "breast implant-associated lymphoma pathology"
  - "breast implant-associated lymphoma radiology"
  - "Dr Scott Turner"
  - "Dr Scott Turner Sydney"
image: https://drturner.com.au/wp-content/uploads/2024/04/blogplaceholder-img.svg
word_count: 2456
---

# BIA-ALCL: Symptoms, Diagnosis and Treatment of Breast Implant-Associated Lymphoma

*[Dr Scott J Turner](https://drturner.com.au/dr-scott-turner-sydney-plastic-surgeon/) | Specialist Plastic Surgeon (FRACS)*

> **Key Takeaways**
>
>
>
>
> - BIA-ALCL is a rare cancer of immune cells that can develop in the fluid or scar capsule around certain breast implants. It is not breast cancer and does not arise from breast tissue.
> - It is overwhelmingly linked to textured implants, particularly the rougher macro-textured type. There are no confirmed Australian cases in patients who have only ever had smooth implants.
> - The most common presentation is new breast swelling from fluid around the implant, usually appearing years after surgery. Most late swelling turns out to be something other than BIA-ALCL, but any new change warrants review.
> - Regulators and surgical bodies do not recommend removing textured implants in patients who have no symptoms. The recommended approach is symptom awareness and standard monitoring.
> - When caught early and treated with complete surgical removal of the implants and capsule, the reported outcomes in the published case series are generally favourable.
> - All risk figures below are best-available estimates rather than precise counts, because the condition is under-reported and the totals rest on estimated implant sales.
If you have found this page you may be worried about cancer. The short version is that BIA-ALCL is rare, it is mostly linked to a specific group of textured implants withdrawn from the Australian market in 2019, and most patients with current implants will never develop it. The longer version, which is what this guide covers, is what the condition actually is, what symptoms to watch for, what your risk looks like given your implant type, and what happens if it ever needs to be investigated.

BIA-ALCL is managed through implant removal and capsulectomy rather than through the augmentation pathway, so the relevant service page is [breast implant revision and removal](https://drturner.com.au/procedures/breast-body/breast-implant-revision/). This article sits alongside the broader overview of [breast augmentation risks and complications](https://drturner.com.au/blogs/breast-augmentation-risks-complications/), which places BIA-ALCL in the context of the other recognised risks.

## What BIA-ALCL is, in plain terms

BIA-ALCL stands for breast implant-associated anaplastic large cell lymphoma. It is a rare cancer of immune cells that can develop in the fluid or scar tissue around certain breast implants. The important word is "around." It is not breast cancer, it does not grow from breast tissue, and it does not behave like breast cancer. Most cases appear between three and fourteen years after the original surgery, with around eight years being the most common. When it is caught early and the implants are removed properly, the published case series report that most patients do well.

The clearest pattern across the worldwide case data is that BIA-ALCL is overwhelmingly linked to textured implants, particularly the rougher macro-textured type. There are no confirmed Australian cases in patients who have only ever had smooth implants. The current understanding is that the disease develops from a combination of long-term inflammation at the textured implant surface, sometimes involving bacterial biofilm, and the patient's own immune or genetic makeup. The surface texture appears to matter more than whether the implant is filled with silicone or saline.

## Your risk depends on the implant you have

The most useful question for understanding your own risk is what type of implant you actually have. The figures below are best-available estimates rather than precise numbers, because BIA-ALCL is under-reported and the totals rest on estimated implant sales rather than exact patient counts. They are broadly accurate as a guide and continue to be refined as more data accumulates.

The TGA's broad category estimates, based on cases reported up to the end of 2021, give a sense of the picture. Polyurethane-coated implants carry the highest estimated risk, at roughly 1 in 1,800; these have not been on the Australian market for years, though some patients still have them. Macro-textured implants sit at around 1 in 2,400, the best known being the Allergan Biocell range, suspended from the Australian market in October 2019 after the data showed disproportionately high rates. Micro-textured implants sit at around 1 in 18,000, and smooth implants have no confirmed Australian cases linked to them.

Manufacturer-specific research narrows this further. Allergan Biocell macro-textured implants are estimated at roughly 1 in 2,000 to 1 in 8,500 depending on the cohort studied, while Mentor Siltex micro-textured implants sit at the low end of the textured range, around 1 in 36,000 to 1 in 50,000. A 2025 systematic review of manufacturers found that approximately 86 per cent of all reported cases globally were linked to Allergan devices, with Mentor accounting for roughly 5 per cent.

What this means in practice is that risk is not uniform across textured implants. Micro-textured implants carry a genuinely low but non-zero risk; older macro-textured implants still in place carry a higher risk than the average textured-implant patient; and smooth implants carry a very low risk of BIA-ALCL specifically. None of these scenarios means surgery is needed in the absence of symptoms.

## Why Australia has a higher share of cases

Roughly 10 to 15 per cent of all reported BIA-ALCL cases worldwide come from Australia. This is not because Australian patients face a higher individual risk. It reflects two specific factors. Until around 2016, about 85 per cent of breast implants used in Australia were textured, whereas in the United States 70 to 90 per cent were smooth, and case rates there are correspondingly lower. Second, Australia has unusually thorough reporting through the TGA and the Australian Breast Device Registry, so cases here are more likely to be recorded than in countries with weaker surveillance. Practice has shifted markedly since 2019: most Australian Specialist Plastic Surgeons now use predominantly smooth implants for cosmetic augmentation, and the high-risk macro-textured implants are no longer available.

## Symptoms to watch for

Most late changes in the breast around implants are not BIA-ALCL. But because the condition often presents first as a sudden new swelling around the implant, it is worth being aware of and checking properly when symptoms appear.

The most common presentation is breast swelling caused by fluid building up around the implant, a seroma, appearing years after the original surgery. Other changes worth noting include:

- A noticeable change in size or shape, usually on one side
- A new lump in the breast or armpit
- Pain that does not settle
- Skin changes such as redness, rash or thickening
- Late-onset capsular contracture, meaning firming or tightening of the scar tissue
- New asymmetry between the two breasts

None of these is specific to BIA-ALCL, and most late seromas turn out to be something else when tested. But any of these changes appearing years after implant surgery is worth checking, particularly with textured or polyurethane-coated implants, because outcomes are generally good when the condition is caught early and delays in diagnosis can allow it to progress.

## How BIA-ALCL is diagnosed

If there is any concern based on your symptoms and examination, the workup follows a fairly standard sequence. The starting point is usually an ultrasound, which can identify fluid collections, masses or unusual lymph nodes around the implant. If fluid is present, an ultrasound-guided needle draws a sample, usually at least 50 millilitres, for laboratory testing. The lab examines the fluid for cytology, CD30 immunohistochemistry and often flow cytometry, to characterise any abnormal cells and rule out other lymphomas. BIA-ALCL cells are typically CD30-positive and ALK-negative, which distinguishes them from other types. If the aspiration result is unclear but suspicion remains, a biopsy of the capsule may be needed.

MRI is sometimes used for more detailed assessment when ultrasound findings need clarification. In Australia, MBS item 63547 applies specifically to MRI for patients with a confirmed diagnosis where MRI is required to assess the disease; it is not a general first-line imaging item for any implant symptom. Once a diagnosis is confirmed, staging investigations, typically a PET-CT scan, establish whether the disease has spread beyond the breast. The pathway is run by a multidisciplinary team including the plastic surgeon, a haematologist with lymphoma expertise, and radiology and pathology services.

## Treatment

Surgery is the cornerstone of treatment, and it is a more involved procedure than routine implant removal. The goal is complete capsulectomy with removal of both implants, in many cases including the side without disease. Where technically feasible, the aim is to remove the implant and capsule in one piece, which may reduce the chance of leaving disease behind. If lymph nodes appear involved, they may be sampled or removed. The clinical position on capsulectomy terminology and surgical approach is set out in the article on [breast implant removal and capsulectomy](https://drturner.com.au/blogs/patient-safety-advisory-breast-implant-removal-and-capsulectomy/).

For patients diagnosed early, when the disease is confined to the capsule and removed completely, the published case series report generally favourable long-term outcomes, with high rates of disease-free survival in this group. More advanced cases, with lymph node involvement or spread beyond the capsule, require additional treatment: chemotherapy, often anthracycline-based regimens combined with CD30-targeted agents such as brentuximab vedotin, and radiotherapy in selected situations. Stem cell transplantation is rarely used and remains under research. Treatment decisions in advanced disease are made by a multidisciplinary team with longer-term follow-up. MBS item 45551 covers the surgical removal of breast implants and the surrounding capsule, and this pathway typically applies for BIA-ALCL with appropriate documentation of the diagnosis and staging.

## What about BIA-SCC?

In September 2022 the FDA flagged a different and even rarer condition: breast implant-associated squamous cell carcinoma, or BIA-SCC. This is not the same disease as BIA-ALCL. BIA-SCC is a different type of cancer, epithelial rather than a lymphoma, meaning it arises from skin-type cells. It is much rarer, with only a small number of cases reported worldwide so far, and the FDA describes it as rare but an emerging concern. It tends to present later, typically 15 to 40 years after implant placement, and early case series suggest it can be more aggressive than BIA-ALCL when diagnosed late. Symptoms include one-sided pain, skin changes, redness and nodules in the implant area. As of early 2026 the TGA has not highlighted confirmed Australian cases, though clinicians are encouraged to report any suspected ones. The same general principle applies: any new breast or skin change years after implant surgery should be assessed.

## What this means for you now

If you currently have breast implants, the right response depends on your situation. The TGA, the Australian Society of Plastic Surgeons and international regulators do not recommend removing textured implants in patients who have no symptoms, purely to prevent BIA-ALCL. This holds whether you have micro-textured implants at the low end of the risk range or older macro-textured implants still in place. Standard monitoring generally means a clinical review every one to two years, plus prompt assessment of anything new such as swelling, pain, lumps or skin changes, rather than routine surveillance imaging in the absence of symptoms.

If you do notice something new, see your plastic surgeon. Most symptoms turn out not to be BIA-ALCL, but a clinical review with appropriate imaging is the right step. If you have smooth implants, your risk of BIA-ALCL specifically is very low, though standard monitoring still applies. If you do not know what type of implant you have, contact the clinic where your surgery was performed, as they should hold the manufacturer, model and surface type in your record; the Australian Breast Device Registry captures many but not all procedures, so your surgical clinic record is the primary source.

For patients considering removal because of BIA-ALCL concerns, the decision is worth working through carefully rather than reactively. The framework for that decision is covered in the guide on [deciding whether to remove breast implants](https://drturner.com.au/blogs/deciding-to-remove-your-breast-implants-yes-or-no/), and the funding considerations in the guide to [Medicare and breast implant removal](https://drturner.com.au/blogs/will-medicare-cover-my-breast-implant-removal/).

## Frequently asked questions

**Do I need to have my implants removed because of BIA-ALCL?**

Probably not, if you have no symptoms. International regulators including the FDA and TGA, along with the Australian Society of Plastic Surgeons, do not recommend removing implants simply because they are textured. The recommended approach is symptom awareness, especially of new breast swelling appearing three or more years after surgery, clinical review if anything changes, and standard monitoring. If you have macro-textured or polyurethane implants and want to discuss removal as a personal choice rather than a medical necessity, that is a reasonable conversation to have at consultation, but it is not something to do reactively.

**What is my actual risk if I have textured implants?**

It depends on the type. The TGA's broad category estimates put polyurethane-coated implants at roughly 1 in 1,800, macro-textured at about 1 in 2,400, and micro-textured at around 1 in 18,000. Manufacturer-specific cohort data narrows this further, with Allergan Biocell macro-textured implants estimated at roughly 1 in 2,000 to 1 in 8,500 and Mentor Siltex micro-textured implants at around 1 in 36,000 to 1 in 50,000. These are best-available estimates rather than precise numbers. There are no confirmed Australian cases in patients with only smooth implants.

**How long after surgery does BIA-ALCL usually appear?**

Most cases, around 95 per cent, appear between three and fourteen years after the original surgery, with the average around eight years. The reported range stretches from one year to 37 years, but presentation in the first three years is uncommon. This is why symptom awareness continues for many years after surgery, particularly with textured or polyurethane-coated implants.

**Is BIA-ALCL the same as breast implant illness?**

No, they are entirely different. BIA-ALCL is a confirmed rare cancer with specific diagnostic criteria, a CD30-positive T-cell lymphoma that usually presents as a late seroma. Breast implant illness is a different category: a cluster of systemic symptoms such as fatigue, joint pain and cognitive difficulty that some patients attribute to their implants, where the evidence base is still developing. The two follow completely different clinical pathways, and breast implant illness is covered in its own [guide](https://drturner.com.au/blogs/latest-update-on-breast-implant-illness-symptoms-and-treatment/).

**What is the prognosis if BIA-ALCL is diagnosed?**

For disease confined to the capsule and treated with complete surgical removal of both implants and capsules, international data indicates that most patients remain disease-free long-term, with generally favourable outcomes when caught early. Advanced disease, with lymph node involvement or spread beyond the capsule, requires additional treatment such as chemotherapy and has more variable outcomes, though these cases still often respond to combined treatment with longer-term haematology follow-up. Early symptom recognition is what makes the difference.

Dr Scott J Turner is a Specialist Plastic Surgeon (FRACS). Where surgery is medically indicated for a confirmed BIA-ALCL diagnosis, it is coordinated with a haematologist with lymphoma expertise. If you have implants and have noticed a new change, or you would like to understand your implant type and what your risk looks like, [contact the practice](https://drturner.com.au/contact-us/) to arrange a consultation. A GP referral is helpful, and bringing any original implant records, operation notes and recent imaging assists the assessment.